Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
31 studies found for:    " June 13, 2012":" July 13, 2012"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
RSS Create an RSS feed from your search for:
" June 13, 2012":" July 13, 2012"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed Positive Change Agents Program-Tanzania (Evaluation)
Condition: HIV Infection
Intervention: Behavioral: Appreciative Inquiry Change Agents (CA) program (NAMWEZA)
2 Unknown  BREATHER (PENTA 16) Short-Cycle Therapy (SCT) (5 Days on/2 Days Off) in Young People With Chronic HIV-infection
Condition: HIV
Intervention: Drug: efavirenz
3 Completed
Has Results
A Pharmacokinetic Study to Evaluate the Effect of Antacids on Raltegravir (MK-0518) in HIV-Infected Participants (MK-0518-247)
Condition: HIV Infections
Interventions: Drug: Raltegravir;   Drug: TUMS® Ultra Strength;   Drug: MINTOX® Maximum Strength
4 Completed A Dose-Ranging Study to Compare Doravirine (MK-1439) Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)
Condition: HIV Infections
Interventions: Drug: Doravirine;   Drug: Efavirenz;   Drug: TRUVADA®
5 Unknown  A Couple-Based Relationship Strengthening HIV Intervention for Young Parents
Condition: HIV
Interventions: Behavioral: Relationship Strengthening HIV Prevention Intervention;   Behavioral: Parenting Program Intervention
6 Active, not recruiting Trends of Morbidity and Mortality Among Thai HIV-infected and HIV-uninfected Patients: a Five-year Prospective Cohort Study
Conditions: HIV Infection;   Healthy
Intervention:
7 Completed
Has Results
Assessment of Pre-Exposure Prophylaxis (PrEP) Administered at Sexually Transmitted Disease (STD) Clinics
Condition: HIV Infections
Intervention: Drug: FTC 200 mg/TDF 300 mg fixed-dose combination tablet
8 Completed Evaluation of Barriers to Postpartum Care in HIV Infected Women
Conditions: HIV Infection;   Pregnancy
Intervention: Other: questionaires and structured interviews
9 Unknown  Enhancing Ugandan HIV-Affected Child Development With Caregiver Training
Condition: HIV
Interventions: Behavioral: MISC;   Behavioral: UCOBAC
10 Active, not recruiting Daily Trimethoprim-sulfamethoxazole or Weekly Chloroquine Among Adults on ART in Malawi
Condition: HIV
Interventions: Drug: Standard of Care prophylaxis;   Drug: Chloroquine (CQ) prophylaxis
11 Unknown  Evaluation of Use of Clinical Decision Support System in HIV Care in Resource Constrained Settings
Condition: HIV
Interventions: Other: EMR Only;   Other: EMR+CDSS
12 Unknown  Addressing Proven Factors in HIV Prevention for Latino Youth
Conditions: HIV;   Sexually Transmitted Infections
Interventions: Behavioral: audio-CD parent education;   Behavioral: health and success parent and school
13 Completed Implementation Effectiveness and Safety of Tenofovir Gel Provision Through Family Planning Services
Condition: HIV
Intervention: Drug: 1% tenofovir gel
14 Completed MARCH Renal Substudy
Conditions: Proteinuria;   HIV
Interventions: Drug: arm 1 nucleotide analogue reverse transcriptase inhibitors and boosted protease inhibitors;   Drug: Arm 2 boosted protease inhibitors and maraviroc;   Drug: Arm 3 nucleotide analogue reverse transcriptase inhibitors and maraviroc
15 Active, not recruiting Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: GSK1265744 10 mg;   Drug: GSK1265744 30 mg;   Drug: GSK1265744 60 mg;   Drug: Efavirenz 600 mg;   Drug: Rilpivirine 25 mg;   Drug: Placebo;   Drug: Abacavir/Lamivudine (ABC/3TC) or Tenofovir/Emtricitabine (TDF/FTC)
16 Completed Immunotherapy With Vacc-C5 With Adjuvant GM-CSF or Alhydrogel in HIV-1-infected Subjects on ART
Condition: HIV-1 Infection
Interventions: Drug: Vacc-C5/GM-CSF;   Drug: Vacc-C5/Alhydrogel
17 Active, not recruiting WelTel Retain: Promoting Engagement in Pre-ART HIV Care Through SMS
Condition: HIV
Intervention: Behavioral: WelTel SMS service
18 Terminated Open-Label Study Comparing Efficacy and Safety of ATV/RTV+3TC With ATV/RTV+TDF/FTC in HIV-Infected, Treatment Naïve Subjects, Followed by Treatment With ATV/RTV+3TC
Condition: HIV
Interventions: Drug: Atazanavir;   Drug: Ritonavir;   Drug: Lamivudine;   Drug: Tenofovir/Emtricitabine
19 Enrolling by invitation Bone Health and Vitamin D Status
Conditions: Osteopenia;   Vitamin D Deficiency;   HIV Infection
Intervention:
20 Completed MARCH Central Nervous System Substudy
Condition: HIV-1 Infection
Interventions: Drug: Arm 1 TNucleotide Analogue Reverse Transcriptase Inhibitors and Boosted Protease Inhibitors;   Drug: Arm 2 Maraviroc and Protease Inhibitors;   Drug: Arm 3 Maraviroc and Nucleotide Analogue Reverse Transcriptase Inhibitors

   Previous Page Studies Shown (1-20) Next Page (21-31) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.